202 related articles for article (PubMed ID: 21190668)
1. Dissociation of bimolecular αIIbβ3-fibrinogen complex under a constant tensile force.
Litvinov RI; Barsegov V; Schissler AJ; Fisher AR; Bennett JS; Weisel JW; Shuman H
Biophys J; 2011 Jan; 100(1):165-73. PubMed ID: 21190668
[TBL] [Abstract][Full Text] [Related]
2. Resolving two-dimensional kinetics of the integrin αIIbβ3-fibrinogen interactions using binding-unbinding correlation spectroscopy.
Litvinov RI; Mekler A; Shuman H; Bennett JS; Barsegov V; Weisel JW
J Biol Chem; 2012 Oct; 287(42):35275-35285. PubMed ID: 22893701
[TBL] [Abstract][Full Text] [Related]
3. Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.
Weber AA; Schrör K
Blood; 2001 Sep; 98(5):1619-21. PubMed ID: 11520817
[TBL] [Abstract][Full Text] [Related]
4. Integrin alphaIIbbeta3-specific synthetic human monoclonal antibodies and HCDR3 peptides that potently inhibit platelet aggregation.
Chung J; Rader C; Popkov M; Hur YM; Kim HK; Lee YJ; Barbas CF
FASEB J; 2004 Feb; 18(2):361-3. PubMed ID: 14688205
[TBL] [Abstract][Full Text] [Related]
5. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
Peter K; Schwarz M; Ylänne J; Kohler B; Moser M; Nordt T; Salbach P; Kübler W; Bode C
Blood; 1998 Nov; 92(9):3240-9. PubMed ID: 9787160
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
Suzuki K; Sato K; Kamohara M; Kaku S; Kawasaki T; Yano S; Iizumi Y
Biol Pharm Bull; 2002 Aug; 25(8):1006-12. PubMed ID: 12186399
[TBL] [Abstract][Full Text] [Related]
7. Strong Binding of Platelet Integrin αIIbβ3 to Fibrin Clots: Potential Target to Destabilize Thrombi.
Höök P; Litvinov RI; Kim OV; Xu S; Xu Z; Bennett JS; Alber MS; Weisel JW
Sci Rep; 2017 Oct; 7(1):13001. PubMed ID: 29021578
[TBL] [Abstract][Full Text] [Related]
8. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
Marciniak SJ; Mascelli MA; Furman MI; Michelson AD; Jakubowski JA; Jordan RE; Marchese PJ; Frelinger AL
Thromb Haemost; 2002 Jun; 87(6):1020-5. PubMed ID: 12083481
[TBL] [Abstract][Full Text] [Related]
9. Bimolecular integrin-ligand interactions quantified using peptide-functionalized dextran-coated microparticles.
Sun JE; Vranic J; Composto RJ; Streu C; Billings PC; Bennett JS; Weisel JW; Litvinov RI
Integr Biol (Camb); 2012 Jan; 4(1):84-92. PubMed ID: 22120019
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic Basis for the Binding of RGD- and AGDV-Peptides to the Platelet Integrin αIIbβ3.
Kononova O; Litvinov RI; Blokhin DS; Klochkov VV; Weisel JW; Bennett JS; Barsegov V
Biochemistry; 2017 Apr; 56(13):1932-1942. PubMed ID: 28277676
[TBL] [Abstract][Full Text] [Related]
11. Activation of individual alphaIIbbeta3 integrin molecules by disruption of transmembrane domain interactions in the absence of clustering.
Litvinov RI; Vilaire G; Li W; DeGrado WF; Weisel JW; Bennett JS
Biochemistry; 2006 Apr; 45(15):4957-64. PubMed ID: 16605263
[TBL] [Abstract][Full Text] [Related]
12. Multi-step fibrinogen binding to the integrin (alpha)IIb(beta)3 detected using force spectroscopy.
Litvinov RI; Bennett JS; Weisel JW; Shuman H
Biophys J; 2005 Oct; 89(4):2824-34. PubMed ID: 16040750
[TBL] [Abstract][Full Text] [Related]
13. Inhibition and reversal of platelet aggregation by alphaIIbbeta3 antagonists depends on the anticoagulant and flow conditions: differential effects of Abciximab and Lamifiban.
Frojmovic M; Labarthe B; Legrand C
Br J Haematol; 2005 Nov; 131(3):348-55. PubMed ID: 16225655
[TBL] [Abstract][Full Text] [Related]
14. The Platelet Integrin αIIbβ3 Differentially Interacts with Fibrin Versus Fibrinogen.
Litvinov RI; Farrell DH; Weisel JW; Bennett JS
J Biol Chem; 2016 Apr; 291(15):7858-67. PubMed ID: 26867579
[TBL] [Abstract][Full Text] [Related]
15. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
Schneider DJ; Taatjes DJ; Sobel BE
Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
[TBL] [Abstract][Full Text] [Related]
17. Time and force dependence of the rupture of glycoprotein IIb-IIIa-fibrinogen bonds between latex spheres.
Goldsmith HL; McIntosh FA; Shahin J; Frojmovic MM
Biophys J; 2000 Mar; 78(3):1195-206. PubMed ID: 10692309
[TBL] [Abstract][Full Text] [Related]
18. Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis.
Abulencia JP; Tien N; McCarty OJ; Plymire D; Mousa SA; Konstantopoulos K
Arterioscler Thromb Vasc Biol; 2001 Jan; 21(1):149-56. PubMed ID: 11145947
[TBL] [Abstract][Full Text] [Related]
19. Allicin and disulfiram enhance platelet integrin alphaIIbbeta3-fibrinogen binding.
Manaster Y; Shenkman B; Rosenberg N; Savion N
Thromb Res; 2009 Sep; 124(4):477-82. PubMed ID: 19632706
[TBL] [Abstract][Full Text] [Related]
20. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
Quinn M; Deering A; Stewart M; Cox D; Foley B; Fitzgerald D
Circulation; 1999 May; 99(17):2231-8. PubMed ID: 10226086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
